Know Your Investor: Invus (July’24 Edition)

Shots:   Backed with an evergreen investment strategy, Invus makes investments across several company stages ranging from early growth to turnarounds In 2023, Invus participated in 6 investment rounds in around 29 companies focusing on biopharma, manufacturing & services, and devices For a curated report on a specific investor or venture capital, reach out to us…

ByPrince GiriJuly 17, 2024

INSIGHTS+

Know Your Investor (March Edition): Qiming Venture Partners

Shots:In this reprise, we feature Qiming Venture Partners again, based on the investments in 2023. With more than 600 investments to date, Qiming boasts a strong portfolio of companies involved in Technology & Consumer and HealthcareIn 2023, Qiming closed 38 funding rounds comprising 11 in the first quarter, 10 in the second, 11…

BySenior EditorMarch 26, 2024

INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in February 2024

Shots:The EMA approved 5 BLA and 8 New Chemical Entities in February 2024, leading to treatments for patients and advances in the healthcare industryIn February 2024, the major highlighted drugs were Reblozyl to treat Transfusion-Dependent Anemia and Velsipity for the treatment of Severely Active Ulcerative ColitisPharmaShots has compiled a list of a total…

BySenior EditorMarch 20, 2024

Know Your Investor: Invus (July’24 Edition)

Know Your Investor (March Edition): Qiming Venture Partners

Insights+: EMA Marketing Authorization of New Drugs in February 2024

Contact US

OUR INFORMATION

FOLLOW US